Related references
Note: Only part of the references are listed.How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials
Myrto T. Samara et al.
SCHIZOPHRENIA BULLETIN (2019)
MRI investigation of immune dysregulation in schizophrenia
Shiral S. Gangadin et al.
CURRENT OPINION IN PSYCHIATRY (2019)
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Yann Chye et al.
FRONTIERS IN PSYCHIATRY (2019)
Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol
Christian Makiol et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2019)
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Marta Di Forti et al.
LANCET PSYCHIATRY (2019)
Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series
Regi Schipper et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal
Chandni Hindocha et al.
ADDICTION (2018)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial
Jose M. Trigo et al.
PLOS ONE (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial
Nadia Solowij et al.
CANNABIS AND CANNABINOID RESEARCH (2018)
Cannabis-associated psychosis: Neural substrate and clinical impact
R. M. Murray et al.
NEUROPHARMACOLOGY (2017)
Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis
E. Foglia et al.
PSYCHOLOGICAL MEDICINE (2017)
Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders
David Crockford et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2017)
Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis
Tabea Schoeler et al.
LANCET PSYCHIATRY (2017)
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia
Mohini Ranganathan et al.
BIOLOGICAL PSYCHIATRY (2016)
Therapeutic Potential of Cannabinoids in Psychosis
F. Markus Leweke et al.
BIOLOGICAL PSYCHIATRY (2016)
Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series
Jose M. Trigo et al.
JOURNAL OF ADDICTION MEDICINE (2016)
Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Arianna Marconi et al.
SCHIZOPHRENIA BULLETIN (2016)
Endocannabinoid signalling in reward and addiction
Loren H. Parsons et al.
NATURE REVIEWS NEUROSCIENCE (2015)
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Felipe V. Gomes et al.
SCHIZOPHRENIA RESEARCH (2015)
A systematic review of the antipsychotic properties of cannabidiol in humans
Tabitha A. Iseger et al.
SCHIZOPHRENIA RESEARCH (2015)
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study
Marta Di Forti et al.
LANCET PSYCHIATRY (2015)
Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies
Matthijs G. Bossong et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or Δ9-tetrahydrocannabinol (THC)
Matthijs G. Bossong et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2014)
Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users
Marta Di Forti et al.
SCHIZOPHRENIA BULLETIN (2014)
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal A Randomized Clinical Trial
David J. Allsop et al.
JAMA PSYCHIATRY (2014)
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
Celia J. A. Morgan et al.
ADDICTIVE BEHAVIORS (2013)
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report
J. A. S. Crippa et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Amir Englund et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
Jenny Ceccarini et al.
NEUROIMAGE (2013)
Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings
Albert Batalla et al.
PLOS ONE (2013)
Multiple Functions of Endocannabinoid Signaling in the Brain
Istvan Katona et al.
ANNUAL REVIEW OF NEUROSCIENCE, VOL 35 (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Cannabis Use and Earlier Onset of Psychosis
Matthew Large et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Cannabis use at a young age is associated with psychotic experiences
C. D. Schubart et al.
PSYCHOLOGICAL MEDICINE (2011)
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Claudio Zanettini et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2011)
Antipsychotics in the Treatment of Schizophrenia: An Overview
Rajiv Tandon
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Cannabis Use and the Course of Schizophrenia: 10-Year Follow-Up After First Hospitalization
Daniel J. Foti et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
The environment and schizophrenia
Jim van Os et al.
NATURE (2010)
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
Dean F. Wong et al.
NEUROIMAGE (2010)
Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia
Matthijs G. Bossong et al.
PROGRESS IN NEUROBIOLOGY (2010)
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Jaime E. C. Hallak et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2010)
Endocannabinoid Signaling and Long-Term Synaptic Plasticity
Boris D. Heifets et al.
ANNUAL REVIEW OF PHYSIOLOGY (2009)
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
Guy A. Cabral et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Endocannabinoid-Mediated Control of Synaptic Transmission
Masanobu Kano et al.
PHYSIOLOGICAL REVIEWS (2009)
Cytokines and schizophrenia: Microglia hypothesis of schizophrenia
Akira Monji et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2009)
Psychiatric Comorbidities and Schizophrenia
Peter F. Buckley et al.
SCHIZOPHRENIA BULLETIN (2009)
Substance Use Disorders in Schizophrenia - Clinical Implications of Comorbidity
Nora D. Volkow
SCHIZOPHRENIA BULLETIN (2009)
Schizophrenia, just the facts 4. Clinical features and conceptualization
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2009)
The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants
Matthew N. Hill et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Roger G. Pertwee
ADDICTION BIOLOGY (2008)
Cannabis and psychiatric disorders: it is not only addiction
F. Markus Leweke et al.
ADDICTION BIOLOGY (2008)
Neurobiological mechanisms of cannabinoid addiction
L. Fattore et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients:: Impact of cannabis use
F. Markus Leweke et al.
SCHIZOPHRENIA RESEARCH (2007)
Cannabidiol monotherapy for treatment-resistant schizophrenia
Antonio Waldo Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Involvement of the endocannabinoid system in drug addiction
R Maldonado et al.
TRENDS IN NEUROSCIENCES (2006)
Size of burden of schizophrenia and psychotic disorders
W Rössler et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Cannabinoid CB1 receptors control conditioned drug seeking
TJ De Vries et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia
M Fioravanti et al.
NEUROPSYCHOLOGY REVIEW (2005)
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
DC D'Souza et al.
BIOLOGICAL PSYCHIATRY (2005)
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
A Giuffrida et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse
GE Hunt et al.
SCHIZOPHRENIA RESEARCH (2002)
Share Paper
